ScinoPharm Taiwan, Ltd. Reports earnings results for the third quarter and nine months ended September 30, 2023 -November 7, 2023 at 11:05 AM

--

closing price


Taiwan Stock Exchange

00:00:00 06-11-2023

Variation 5 days

Difference compared to January 1 (%)

26.65 TWD

+1.52%

0.00%

+4.72%

November 7, 2023 at 11:05 am

ScinoPharm Taiwan, Ltd. reported results for the third quarter and the nine months ended September 30, 2023. For the third quarter, the company reported revenues of TWD 659.59 million, compared to TWD 704.72 million a year ago. Net profit amounted to TWD 30.72 million, compared to TWD 60.56 million a year ago. Basic earnings per share from continuing operations amounted to TWD 0.04, compared to TWD 0.08 a year ago. Diluted earnings per share from continuing operations amounted to TWD 0.04, compared to TWD 0.08 a year ago. Basic earnings per share amounted to TWD 0.04 compared to TWD 0.08 a year ago. Diluted earnings per share amounted to TWD 0.04 compared to TWD 0.08 a year ago.
For the nine months, sales amounted to TWD 2,062.92 million, compared to TWD 2,248.19 million a year ago. Net profit amounted to TWD 129.68 million, compared to TWD 251.64 million a year ago. Basic earnings per share from continuing operations amounted to TWD 0.16, compared to TWD 0.32 a year ago. Diluted earnings per share from continuing operations amounted to TWD 0.16, compared to TWD 0.32 a year ago. Basic earnings per share amounted to TWD 0.16 compared to TWD 0.32 a year ago. Diluted earnings per share amounted to TWD 0.16 compared to TWD 0.32 a year ago.

ScinoPharm Taiwan, Ltd. Reports earnings results for the third quarter and nine months ended September 30, 2023

11:05

CI

ScinoPharm Taiwan, Ltd. Reports earnings results for the second quarter and the six months ended June 30, 2023

08/08

CI

Yearly payment

06/07

FA

ScinoPharm Taiwan, Ltd. Announces Compensation Committee appointments

29/05

CI

ScinoPharm Taiwan, Ltd. Announces the appointment of independent directors

29/05

CI

ScinoPharm Taiwan, Ltd. Authorizes 2022 cash dividend, payable on July 28, 2023

29/05

CI

ScinoPharm Taiwan, Ltd. Reports earnings results for the first quarter ended March 31, 2023

11/05

CI

ScinoPharm Taiwan, Ltd. Reports results for the full year ended December 31, 2022

01/03

CI

ScinoPharm Taiwan, Ltd. Reports earnings results for the third quarter and nine months ended September 30, 2022

08/11

CI

ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

2022

CI

Yearly payment

2022

FA

Scinopharm Taiwan, Ltd approves cash dividend, payable on August 2, 2022

2022

CI

ScinoPharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022

2022

CI

ScinoPharm Taiwan, Ltd. reports earnings for the full year ended December 31, 2021

2022

CI

ScinoPharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

2021

CI

Yearly payment

2021

FA

Scinopharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021

2021

CI

ScinoPharm Taiwan, Ltd. announces cash dividend, payable on September 23, 2021

2021

CI

Scinopharm Taiwan, Ltd. Agrees to payment of cash dividend

2021

CI

Scinopharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021

2021

CI

Scinopharm Taiwan, Ltd. Reports Earnings Results for the Full Year Ending December 31, 2020

2021

CI

Scinopharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020

2020

CI

Scinopharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020

2020

CI

Yearly payment

2020

FA

ScinoPharm Taiwan, Ltd. announces cash dividend, payable on August 19, 2020

2020

CI

Duration Car. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.

Period Day Week

More graphs

ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, production and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The company is also engaged in providing consultancy and biotechnology services for related products, international trade of products, as well as providing customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates in the domestic and overseas markets, including North and South America, Europe, Australia and Asia.

Learn more about the company

Sale

Buy

Latest closing price

26.65TWD

Average price target

26.00TWD

Spread / Average target

-2.44%

Consensus

Vaira. Jan 1

Kapi. (M$)

+4.72% $656M
+62.69% 535 md. $
+50.26% 451 md. $
-14.12% 365 md. $
-5.96% 264 mo. $
-12.63% 249 md. $
-18.35% 213 mo. $
-8.66% 197 mo. $
+1.15% 193 md. $
-39.15% 176 mo. $

Pharmaceutical products – Other

-

PREV NOS is looking for a new cycling commentator. Who should it be? These are the suggestions
NEXT Filipino golfers falter in Taiwan, Japan